ArticleCell death & disease2019

Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.

Kai Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.